StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Investment analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued on Wednesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Price Performance

Lipocine stock opened at $4.86 on Wednesday. Lipocine has a one year low of $2.82 and a one year high of $11.79. The firm has a market capitalization of $25.99 million, a P/E ratio of -6.39 and a beta of 1.24. The business has a fifty day moving average price of $5.06 and a 200-day moving average price of $5.28.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. Sell-side analysts expect that Lipocine will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.